Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 238

1.

Dissociable cognitive patterns related to depression and anxiety in multiple sclerosis.

Leavitt VM, Brandstadter R, Fabian M, Katz Sand I, Klineova S, Krieger S, Lewis C, Lublin F, Miller A, Pelle G, Buyukturkoglu K, De Jager PL, Li P, Riley CS, Tsapanou A, Sumowski JF.

Mult Scler. 2019 Jun 24:1352458519860319. doi: 10.1177/1352458519860319. [Epub ahead of print]

PMID:
31233379
2.

Brain and lesion segmentation in multiple sclerosis using fully convolutional neural networks: A large-scale study.

Gabr RE, Coronado I, Robinson M, Sujit SJ, Datta S, Sun X, Allen WJ, Lublin FD, Wolinsky JS, Narayana PA.

Mult Scler. 2019 Jun 13:1352458519856843. doi: 10.1177/1352458519856843. [Epub ahead of print]

PMID:
31190607
3.

Psychological resilience is linked to motor strength and gait endurance in early multiple sclerosis.

Klineova S, Brandstadter R, Fabian MT, Sand IK, Krieger S, Leavitt VM, Lewis C, Riley CS, Lublin F, Miller AE, Sumowski JF.

Mult Scler. 2019 Jun 7:1352458519852725. doi: 10.1177/1352458519852725. [Epub ahead of print]

PMID:
31172846
4.

Axonal water fraction as marker of white matter injury in primary-progressive multiple sclerosis: a longitudinal study.

Margoni M, Petracca M, Schiavi S, Fabian M, Miller A, Lublin FD, Inglese M.

Eur J Neurol. 2019 Feb 13. doi: 10.1111/ene.13937. [Epub ahead of print]

PMID:
30761708
5.

Open-label, add-on trial of cetirizine for neuromyelitis optica.

Katz Sand I, Fabian MT, Telford R, Kraus TA, Chehade M, Masilamani M, Moran T, Farrell C, Ebel S, Cook LJ, Rose J, Lublin FD.

Neurol Neuroimmunol Neuroinflamm. 2018 Feb 2;5(2):e441. doi: 10.1212/NXI.0000000000000441. eCollection 2018 Mar.

6.

Objective and subjective measures of dalfampridine efficacy in clinical practice.

Klineova S, Farber R, Friedman J, Farrell C, Lublin FD, Krieger S.

Mult Scler J Exp Transl Clin. 2018 Jul 9;4(3):2055217318786742. doi: 10.1177/2055217318786742. eCollection 2018 Jul-Sep.

7.

"Location, location, location".

Krieger SC, Lublin FD.

Mult Scler. 2018 Oct;24(11):1396-1398. doi: 10.1177/1352458518790385. Epub 2018 Jul 26. No abstract available.

PMID:
30047828
8.

No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a.

Havrdová E, Arnold DL, Bar-Or A, Comi G, Hartung HP, Kappos L, Lublin F, Selmaj K, Traboulsee A, Belachew S, Bennett I, Buffels R, Garren H, Han J, Julian L, Napieralski J, Hauser SL, Giovannoni G.

Mult Scler J Exp Transl Clin. 2018 Mar 12;4(1):2055217318760642. doi: 10.1177/2055217318760642. eCollection 2018 Jan-Mar.

9.

Brain atrophy and disability worsening in primary progressive multiple sclerosis: insights from the INFORMS study.

Miller DH, Lublin FD, Sormani MP, Kappos L, Yaldizli Ö, Freedman MS, Cree BAC, Weiner HL, Lubetzki C, Hartung HP, Montalban X, Uitdehaag BMJ, MacManus DG, Yousry TA, Gandini Wheeler-Kingshott CAM, Li B, Putzki N, Merschhemke M, Häring DA, Wolinsky JS.

Ann Clin Transl Neurol. 2018 Jan 30;5(3):346-356. doi: 10.1002/acn3.534. eCollection 2018 Mar.

10.

Brain microstructural injury occurs in patients with RRMS despite 'no evidence of disease activity'.

Harel A, Sperling D, Petracca M, Ntranos A, Katz-Sand I, Krieger S, Lublin F, Wang Z, Liu Y, Inglese M.

J Neurol Neurosurg Psychiatry. 2018 Sep;89(9):977-982. doi: 10.1136/jnnp-2017-317606. Epub 2018 Mar 16.

PMID:
29549189
11.

Editors' Welcome.

Giovannoni G, Hawkes C, Levy M, Lublin F, Waubant E.

Mult Scler Relat Disord. 2018 Jan;19:A1-A2. doi: 10.1016/j.msard.2018.01.004. No abstract available.

PMID:
29409600
12.

Clinical Course of Multiple Sclerosis.

Klineova S, Lublin FD.

Cold Spring Harb Perspect Med. 2018 Sep 4;8(9). pii: a028928. doi: 10.1101/cshperspect.a028928. Review.

PMID:
29358317
13.

Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria.

Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, Correale J, Fazekas F, Filippi M, Freedman MS, Fujihara K, Galetta SL, Hartung HP, Kappos L, Lublin FD, Marrie RA, Miller AE, Miller DH, Montalban X, Mowry EM, Sorensen PS, Tintoré M, Traboulsee AL, Trojano M, Uitdehaag BMJ, Vukusic S, Waubant E, Weinshenker BG, Reingold SC, Cohen JA.

Lancet Neurol. 2018 Feb;17(2):162-173. doi: 10.1016/S1474-4422(17)30470-2. Epub 2017 Dec 21. Review.

PMID:
29275977
14.

Editors' Welcome.

Waubant E, Giovannoni G, Hawkes C, Lublin F.

Mult Scler Relat Disord. 2017 Nov;18:A1-A2. doi: 10.1016/j.msard.2017.10.016. No abstract available.

PMID:
29141832
15.

Long-term follow-up of a randomized study of combination interferon and glatiramer acetate in multiple sclerosis: Efficacy and safety results up to 7 years.

Lublin FD, Cofield SS, Cutter GR, Gustafson T, Krieger S, Narayana PA, Nelson F, Salter AR, Wolinsky JS.

Mult Scler Relat Disord. 2017 Nov;18:95-102. doi: 10.1016/j.msard.2017.09.012. Epub 2017 Sep 23.

16.

Editors' Welcome.

Lublin F, Giovannoni G, Hawkes C, Waubant E.

Mult Scler Relat Disord. 2017 Oct;17:A1-A2. doi: 10.1016/j.msard.2017.09.025. No abstract available.

PMID:
29055486
17.

Looking into cognitive impairment in primary-progressive multiple sclerosis.

Petracca M, Sumowski J, Fabian M, Miller A, Lublin F, Inglese M.

Eur J Neurol. 2018 Jan;25(1):192-195. doi: 10.1111/ene.13489. Epub 2017 Dec 6.

PMID:
29053884
18.

Cerebellar lobule atrophy and disability in progressive MS.

Cocozza S, Petracca M, Mormina E, Buyukturkoglu K, Podranski K, Heinig MM, Pontillo G, Russo C, Tedeschi E, Russo CV, Costabile T, Lanzillo R, Harel A, Klineova S, Miller A, Brunetti A, Morra VB, Lublin F, Inglese M.

J Neurol Neurosurg Psychiatry. 2017 Dec;88(12):1065-1072. doi: 10.1136/jnnp-2017-316448. Epub 2017 Aug 26.

PMID:
28844067
19.

The MSOAC approach to developing performance outcomes to measure and monitor multiple sclerosis disability.

LaRocca NG, Hudson LD, Rudick R, Amtmann D, Balcer L, Benedict R, Bermel R, Chang I, Chiaravalloti ND, Chin P, Cohen JA, Cutter GR, Davis MD, DeLuca J, Feys P, Francis G, Goldman MD, Hartley E, Kapoor R, Lublin F, Lundstrom G, Matthews PM, Mayo N, Meibach R, Miller DM, Motl RW, Mowry EM, Naismith R, Neville J, Panagoulias J, Panzara M, Phillips G, Robbins A, Sidovar MF, Smith KE, Sperling B, Uitdehaag BM, Weaver J; Multiple Sclerosis Outcome Assessments Consortium (MSOAC).

Mult Scler. 2018 Oct;24(11):1469-1484. doi: 10.1177/1352458517723718. Epub 2017 Aug 11.

20.

The relationship between cortical lesions and periventricular NAWM abnormalities suggests a shared mechanism of injury in primary-progressive MS.

Pardini M, Petracca M, Harel A, Fleysher L, Oesingmann N, Bommarito G, Fabian M, Chard D, Lublin F, Inglese M.

Neuroimage Clin. 2017 Jul 4;16:111-115. doi: 10.1016/j.nicl.2017.07.001. eCollection 2017.

21.

Editors' Welcome.

Hawkes C, Giovannoni G, Lublin F, Waubant E.

Mult Scler Relat Disord. 2017 Aug;16:A1-A2. doi: 10.1016/j.msard.2017.07.015. No abstract available.

PMID:
28755685
22.

Sporadic Creutzfeldt-Jakob Disease With Unilateral Symptoms in the Setting of Metastatic Renal Cell Carcinoma.

Rossi KC, Stahl CM, Zhang P, Liang JW, Marcuse LV, Lublin F.

Neurologist. 2017 Jul;22(4):131-133. doi: 10.1097/NRL.0000000000000124.

PMID:
28644254
23.

The 'Field Hypothesis': rebound activity after stopping disease-modifying therapies.

Giovannoni G, Hawkes C, Waubant E, Lublin F.

Mult Scler Relat Disord. 2017 Jul;15:A1-A2. doi: 10.1016/j.msard.2017.06.005. No abstract available.

PMID:
28641776
24.

Editors' welcome.

Waubant E, Giovannoni G, Hawkes C, Lublin F.

Mult Scler Relat Disord. 2017 May;14:A1-A2. doi: 10.1016/j.msard.2017.04.005. Epub 2017 Apr 21. No abstract available.

PMID:
28619438
25.

A composite measure to explore visual disability in primary progressive multiple sclerosis.

Poretto V, Petracca M, Saiote C, Mormina E, Howard J, Miller A, Lublin FD, Inglese M.

Mult Scler J Exp Transl Clin. 2017 May 18;3(2):2055217317709620. doi: 10.1177/2055217317709620. eCollection 2017 Apr-Jun.

26.

Relationship between timed 25-foot walk and diffusion tensor imaging in multiple sclerosis.

Klineova S, Farber R, Saiote C, Farrell C, Delman BN, Tanenbaum LN, Friedman J, Inglese M, Lublin FD, Krieger S.

Mult Scler J Exp Transl Clin. 2016 Jun 23;2:2055217316655365. doi: 10.1177/2055217316655365. eCollection 2016 Jan-Dec.

27.

Cerebellar volume as imaging outcome in progressive multiple sclerosis.

Inglese M, Petracca M, Mormina E, Achiron A, Straus-Farber R, Miron S, Fabian M, Krieger S, Miller A, Lublin F, Sormani MP.

PLoS One. 2017 Apr 24;12(4):e0176519. doi: 10.1371/journal.pone.0176519. eCollection 2017.

28.

Synchronization and variability imbalance underlie cognitive impairment in primary-progressive multiple sclerosis.

Petracca M, Saiote C, Bender HA, Arias F, Farrell C, Magioncalda P, Martino M, Miller A, Northoff G, Lublin F, Inglese M.

Sci Rep. 2017 Apr 21;7:46411. doi: 10.1038/srep46411.

29.

Editors' Welcome.

Lublin F, Giovannoni G, Hawkes C, Waubant E.

Mult Scler Relat Disord. 2017 Apr;13:A1. doi: 10.1016/j.msard.2017.03.010. No abstract available.

PMID:
28427712
30.

Editors' Welcome.

Hawkes C, Giovannoni G, Lublin F, Waubant E.

Mult Scler Relat Disord. 2017 Feb;12:A1-A2. doi: 10.1016/j.msard.2017.02.011. No abstract available.

PMID:
28283115
31.

A Framework of Care in Multiple Sclerosis, Part 2: Symptomatic Care and Beyond.

Newsome SD, Aliotta PJ, Bainbridge J, Bennett SE, Cutter G, Fenton K, Lublin F, Northrop D, Rintell D, Walker BD, Weigel M, Zackowski K, Jones DE.

Int J MS Care. 2017 Jan-Feb;19(1):42-56. doi: 10.7224/1537-2073.2016-062.

32.

Editors' Welcome.

Giovannoni G, Hawkes C, Lublin F, Waubant E.

Mult Scler Relat Disord. 2017 Jan;11:A1-A2. doi: 10.1016/j.msard.2016.12.008. No abstract available.

PMID:
28104262
33.

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis.

Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, de Seze J, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Rammohan KW, Selmaj K, Traboulsee A, Sauter A, Masterman D, Fontoura P, Belachew S, Garren H, Mairon N, Chin P, Wolinsky JS; ORATORIO Clinical Investigators.

N Engl J Med. 2017 Jan 19;376(3):209-220. doi: 10.1056/NEJMoa1606468. Epub 2016 Dec 21.

34.

Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.

Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Montalban X, Rammohan KW, Selmaj K, Traboulsee A, Wolinsky JS, Arnold DL, Klingelschmitt G, Masterman D, Fontoura P, Belachew S, Chin P, Mairon N, Garren H, Kappos L; OPERA I and OPERA II Clinical Investigators.

N Engl J Med. 2017 Jan 19;376(3):221-234. doi: 10.1056/NEJMoa1601277. Epub 2016 Dec 21.

35.

CME/CNE Article: A Framework of Care in Multiple Sclerosis, Part 1: Updated Disease Classification and Disease-Modifying Therapy Use in Specific Circumstances.

Newsome SD, Aliotta PJ, Bainbridge J, Bennett SE, Cutter G, Fenton K, Lublin F, Northrop D, Rintell D, Walker BD, Weigel M, Zackowski K, Jones DE.

Int J MS Care. 2016 Nov-Dec;18(6):314-323. doi: 10.7224/1537-2073.2016-051.

36.

Editors' Welcome.

Hawkes C, Lublin F, Giovannoni G, Waubant E.

Mult Scler Relat Disord. 2016 Nov;10:A1. doi: 10.1016/j.msard.2016.11.007. No abstract available.

PMID:
27919509
37.

Baseline EDSS proportions in MS clinical trials affect the overall outcome and power: A cautionary note.

Wang G, Cutter GR, Cofield SS, Lublin F, Wolinsky JS, Gustafson T, Krieger S, Salter A.

Mult Scler. 2017 Jun;23(7):982-987. doi: 10.1177/1352458516670733. Epub 2016 Sep 28.

38.

Editors' Welcome.

Hawkes C, Lublin F, Giovannoni G.

Mult Scler Relat Disord. 2016 Sep;9:A1. doi: 10.1016/j.msard.2016.08.014. No abstract available.

PMID:
27645368
39.

Diagnostic Criteria, Classification and Treatment Goals in Multiple Sclerosis: The Chronicles of Time and Space.

Ntranos A, Lublin F.

Curr Neurol Neurosci Rep. 2016 Oct;16(10):90. doi: 10.1007/s11910-016-0688-8. Review.

PMID:
27549391
40.

Editors' Welcome.

Hawkes C, Lublin F, Giovannoni G.

Mult Scler Relat Disord. 2016 Jul;8:A1-2. doi: 10.1016/j.msard.2016.06.008. No abstract available.

PMID:
27456892
41.

Editors' Welcome.

Banwell B, Giovannoni G, Hawkes C, Lublin F.

Mult Scler Relat Disord. 2016 May;7:A1-2. doi: 10.1016/j.msard.2016.05.011. No abstract available.

PMID:
27237771
42.

Editors' Welcome.

Banwell B, Giovannoni G, Hawkes C, Lublin F.

Mult Scler Relat Disord. 2016 Mar;6:A1-2. doi: 10.1016/j.msard.2016.03.002. No abstract available.

PMID:
27063633
43.

Relapses in multiple sclerosis: Relationship to disability.

Goodin DS, Reder AT, Bermel RA, Cutter GR, Fox RJ, John GR, Lublin FD, Lucchinetti CF, Miller AE, Pelletier D, Racke MK, Trapp BD, Vartanian T, Waubant E.

Mult Scler Relat Disord. 2016 Mar;6:10-20. doi: 10.1016/j.msard.2015.09.002. Epub 2015 Sep 8. Review.

PMID:
27063617
44.

Phase-Sensitive Inversion-Recovery MRI Improves Longitudinal Cortical Lesion Detection in Progressive MS.

Harel A, Ceccarelli A, Farrell C, Fabian M, Howard J, Riley C, Miller A, Lublin F, Inglese M.

PLoS One. 2016 Mar 22;11(3):e0152180. doi: 10.1371/journal.pone.0152180. eCollection 2016.

45.

Retinal degeneration in primary-progressive multiple sclerosis: A role for cortical lesions?

Petracca M, Cordano C, Cellerino M, Button J, Krieger S, Vancea R, Ghassemi R, Farrell C, Miller A, Calabresi PA, Lublin F, Inglese M.

Mult Scler. 2017 Jan;23(1):43-50. doi: 10.1177/1352458516637679. Epub 2016 Jul 11.

PMID:
26993116
46.

Editors' Welcome.

Banwell B, Giovannoni G, Hawkes C, Lublin F.

Mult Scler Relat Disord. 2016 Jan;5:A1. doi: 10.1016/j.msard.2016.01.002. No abstract available.

PMID:
26856953
47.

Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial.

Lublin F, Miller DH, Freedman MS, Cree BAC, Wolinsky JS, Weiner H, Lubetzki C, Hartung HP, Montalban X, Uitdehaag BMJ, Merschhemke M, Li B, Putzki N, Liu FC, Häring DA, Kappos L; INFORMS study investigators.

Lancet. 2016 Mar 12;387(10023):1075-1084. doi: 10.1016/S0140-6736(15)01314-8. Epub 2016 Jan 28. Erratum in: Lancet. 2017 Jan 21;389(10066):254.

PMID:
26827074
48.

Onset of clinical and MRI efficacy occurs early after fingolimod treatment initiation in relapsing multiple sclerosis.

Kappos L, Radue EW, Chin P, Ritter S, Tomic D, Lublin F.

J Neurol. 2016 Feb;263(2):354-360. doi: 10.1007/s00415-015-7978-y. Epub 2015 Dec 8.

49.

Editors' Welcome.

Banwell B, Giovannoni G, Hawkes C, Lublin F.

Mult Scler Relat Disord. 2015 Nov;4(6):A1-2. doi: 10.1016/j.msard.2015.11.001. No abstract available.

PMID:
26590672
50.

William Austin Sibley, MD (1925-2015).

Reingold SC, Lublin FD.

Mult Scler. 2016 Jan;22(1):11-2. doi: 10.1177/1352458515616206. Epub 2015 Nov 16. No abstract available.

PMID:
26573143

Supplemental Content

Loading ...
Support Center